Health
Swipe up to read →
Three months ago, a group of practitioners published a quiet result that, in hindsight, marks a real inflection point on why glp-1 drugs are reshaping more than just weight loss.
What's tricky is that the leading indicators are noisy. Vendor revenue is up, but so is churn. Talent moves both ways. Job postings list contradictory requirements. The strongest signal is what experienced practitioners do with their own…
Three quiet trends are converging: cheaper compute, better tooling, and a new generation of operators who grew up with these tools as defaults. Each was a slow burn on its own. Together they compound, and that compounding is what most…
Three quiet trends are converging: cheaper compute, better tooling, and a new generation of operators who grew up with these tools as defaults. Each was a slow burn on its own. Together they compound, and that compounding is what most…
We don't need another framework — we need a better default. For most teams, the right move is to test the contrarian position with one project and let the results decide.
Three months ago, a group of practitioners published a quiet result that, in hindsight, marks a real inflection point on why glp-1 drugs…